Rosetta Genomics Ltd. to Receive Important U.S. Patent for Oncology Therapeutic
Published: Feb 26, 2014
PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Feb 26, 2014) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent claiming Mp53-negative cancer patients. The allowed claims for U.S. Patent Application No. 12/528,690 entitled "Composition and Methods for Modulating Cell Proliferation and Cell Death," cover a core element of Rosetta Genomics' microRNA technology in the development of cancer therapeutics associated with non-small cell lung cancer (NSCLC) in p53-negative patients. The allowed patent application is jointly owned with Yeda, the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel.
Help employers find you! Check out all the jobs and post your resume.